Literature DB >> 25146360

Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.

Yanguang Cao1, William J Jusko.   

Abstract

Minimal physiologically based pharmacokinetic (mPBPK) models provide a simple and sensible approach that incorporates physiological elements into pharmacokinetic (PK) analysis when only plasma data are available. With this modeling concept, a second-generation mPBPK model was further developed with specific accommodations for the unique PK properties of monoclonal antibodies (mAb). This study applied this model to extensively survey mAb PK in man in order to seek general perspectives on mAb distributional and elimination features. Profiles for 72 antibodies were successfully analyzed with this model. The model results provide assessment regarding: (1) predominant clearance site, in plasma or interstitial fluid (ISF); (2) mAb ISF concentrations in two groups of lumped tissues with continuous (V(tight)) or fenestrated (V(leaky)) vascular endothelium; (3) Transcapillary escape rate (TER), an indicator of systemic vascular permeability. For 93% of surveyed mAbs, the model assuming clearance from plasma (CL) produced better or at least equivalent model performance than the model with clearance from ISF and yielded most consistent values of vascular reflection coefficients (σ1 and σ2) among all antibodies. The average mAb ISF concentration in V(tight) and V(leaky) at equilibrium was predicted to be about 6.8 and 37.9% of that in plasma. A positive correlation was detected between plasma clearance and TER among most mAbs, which could be interpreted as both parameters having common determinants related to ISF tissue distribution in this model context. The mAbs with relative higher plasma clearance (>0.035 L/h/70 kg) did not reveal such positive correlation between clearance and TER, implying that the factors contributing to high clearance may not necessarily increase tissue distribution and penetration. In conclusion, this mPBPK model offers a more mechanistic approach for analyzing plasma mAb PK than compartment models and generates parameters providing useful intrinsic distributional and elimination insights for a large number of mAbs that were examined in man.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25146360      PMCID: PMC4226811          DOI: 10.1007/s10928-014-9374-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  22 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

Review 2.  Antibody therapeutics in cancer.

Authors:  Mark X Sliwkowski; Ira Mellman
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

3.  Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

Authors:  Wolfgang F Richter; Hans Peter Grimm; Frank-Peter Theil
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-07-21       Impact factor: 2.745

Review 4.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

5.  Interstitial exclusion of IgG in rat tissues estimated by continuous infusion.

Authors:  H Wiig; G A Kaysen; H A al-Bander; M De Carlo; L Sibley; E M Renkin
Journal:  Am J Physiol       Date:  1994-01

6.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.

Authors:  Michael M Schmidt; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

7.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

8.  Marketed therapeutic antibodies compendium.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

9.  Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability.

Authors:  Hemant Sarin
Journal:  J Angiogenes Res       Date:  2010-08-11

10.  Mediation of pinocytosis in cultured arterial smooth muscle and endothelial cells by platelet-derived growth factor.

Authors:  P F Davies; R Ross
Journal:  J Cell Biol       Date:  1978-12       Impact factor: 10.539

View more
  23 in total

Review 1.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

2.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

3.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

4.  A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species.

Authors:  Brian M Maas; Yanguang Cao
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

Review 5.  Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Drug Metab Pharmacokinet       Date:  2018-11-22       Impact factor: 3.614

6.  A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  Eur J Pharm Sci       Date:  2019-08-05       Impact factor: 4.384

7.  A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

8.  In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.

Authors:  Daniel J Rubins; Xiangjun Meng; Paul McQuade; Michael Klimas; Krista Getty; Shu-An Lin; Brett M Connolly; Stacey S O'Malley; Hyking Haley; Mona Purcell; Liza Gantert; Marie Holahan; Joel Lindgren; Pär Eklund; Caroline Ekblad; Fredrik Y Frejd; Eric D Hostetler; Dinko E González Trotter; Jeffrey L Evelhoch
Journal:  Mol Imaging Biol       Date:  2020-10-23       Impact factor: 3.488

9.  A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model.

Authors:  Songmao Zheng; Jin Niu; Brian Geist; Damien Fink; Zhenhua Xu; Honghui Zhou; Weirong Wang
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

10.  Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.

Authors:  Shun Xin Wang-Lin; Chenguang Zhou; Amrita V Kamath; Kyu Hong; Neelima Koppada; Ola M Saad; Montserrat Carrasco-Triguero; Cyrus Khojasteh; Rong Deng
Journal:  MAbs       Date:  2018-08-06       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.